# 3) Generative Unconstrained Intelligent Drug Engineering - Enhanced Biological Defense (GUIDE-ENBD)

**R-2A activity** of project PT4 — Protect (ACD&P)  
**Program element:** 0603884BP — Chemical and Biological Defense Program - Dem/Val  
**Component:** Defense-Wide · **Budget Activity:** 4  
**Vintage:** President's Budget PB2027  
**Canonical URL:** https://hitchintel.com/programs/0603884BP/PT4/a2  
**Parent:** https://hitchintel.com/programs/0603884BP/PT4

## Summary

This activity requests $45.5M in FY2027, 35% of project PT4, down 25% on FY2026. The R-2A exhibit describes it across FY2025–FY2027, including what the FY2027 money is planned to buy.

## What the FY2027 request buys

**FY2027 planned work.** Continue planning, coding, building, and testing new and existing digital tools and corresponding experimental capabilities to increase speed and accuracy of computational medical countermeasure (MCM) discovery efforts to enable rapid response capability. Continue design of new MCMs for transition to the Rapid Access to Products in Development (RAPID) program and subsequent clinical development efforts.

**FY2026 to FY2027 change.** Decrease from FY 2026 to FY 2027 due to efficiencies gained as a result of developmental maturity of computational tools for MCM design and optimization capability.

## Before the request year

**FY2026 plans — current year.** Continue planning, coding, building, and testing of new and existing digital tools and algorithms and corresponding experimental capabilities to increase speed and accuracy of computational medical countermeasure (MCM) discovery efforts and rapid response capability. Continue design of new MCMs which will be positioned in the Rapid Access to Products in Development (RAPID) program, within Project PT5/Protect (System Development & Demonstration).

**FY2025 accomplishments.** Continued planning, coding, building, and testing of new and existing digital tools and algorithms and corresponding experimental capabilities to increase speed and accuracy of computational medical countermeasure (MCM) discovery efforts and rapid response capability. Continue design of new MCMs which will be positioned in the Rapid Access to Products in Development (RAPID) program, within Project PT5/Protect (System Development & Demonstration).

## Funding

| Fiscal Year | Estimate Type | Amount ($M) |
|---|---|---|
| FY2025 | Actual | 61.8 |
| FY2026 | Enacted | 60.8 |
| FY2027 | Request | 45.5 |

> Prior, current and budget year only — an R-2A activity carries no five-year plan. It sums exactly into its project in the request year and not necessarily in any other.

## Other activities in project PT4

- [1) Accelerated Antibodies - Enhanced Biological Defense (AA-ENBD)](https://hitchintel.com/programs/0603884BP/PT4/a0) — FY2027 32.1
- [8) Vaccine Acceleration By Modular Progression - Enhanced Biological Defense (VAMP-ENBD)](https://hitchintel.com/programs/0603884BP/PT4/a7) — FY2027 31.1
- 5) Medical Countermeasures Platform Technologies (MCMPT) - Host Directed Countermeasure — FY2027 9.0
- 7) Prophylactic Technology Systems (ProTecS) — FY2027 7.3
- 4) Medical Countermeasures Platform Technologies (MCMPT) - Prevention Platform — FY2027 3.8
- 6) Plague Monoclonal Antibodies (PLG MAB) — FY2027 0.5
- 2) Biological Containment Isolation System - Enhanced Biological Defense (BCIS-ENBD) — FY2027 —
- 9) Portable Patient Transport System - Enhanced Biological Defense (PPTS-ENBD) — FY2027 —
- 10) Shipboard Isolation System (SIS) — FY2027 —

## Source & machine access

- **Source:** FY2027 Office of the Secretary of Defense RDT&E Budget Justification, Exhibit R-2A, PE 0603884BP project PT4 (PB PB2027). Narrative is the government's own text.
- **No marks, no contractors at this grain** — congressional marks land on the program element and R-3 performers on the project.
- **MCP:** `mcp.hitchintel.com` — `budget_get_activity`.

*HitchAI is an independent intelligence service, not affiliated with the U.S. Department of Defense. Budget figures are requests/estimates, not obligations.*